PremiumMedTech & Devices
MHRA Clears Retifanlimab for Advanced Merkel Cell Carcinoma, Opening New Immunotherapy Option for Rare Skin Cancer
The UK regulator has approved Incyte's PD-1 inhibitor ZYNYZ for a neuroendocrine skin malignancy with historically poor outcomes.
VanadiumNews Research Team · 4 min · 8 Jul 2026